Abstract Age-related changes in cardiac homeostasis can be observed at the cellular, extracellular, and tissue levels. Progressive cardiomyocyte hypertrophy, inflammation, and the gradual development of cardiac fibrosis are hallmarks of cardiac aging. In the absence of a secondary insult such as hypertension, these changes are subtle and result in slight to moderate impaired myocardial function, particularly diastolic function. While collagen deposition and cross-linking increase during aging, extracellular matrix (ECM) degradation capacity also increases due to increased expression of matrix metalloproteinases (MMPs). Of the MMPs elevated with cardiac aging, MMP-9 has been extensively evaluated and its roles are reviewed here. In addition to proteolytic activity on ECM components, MMPs oversee cell signaling during the aging process by modulating cytokine, chemokine, growth factor, hormone, and angiogenic factor expression and activity. In association with elevated MMP-9, macrophage numbers increase in an age-dependent manner to regulate the ECM and angiogenic responses. Understanding the complexity of the molecular interactions between MMPs and the ECM in the context of aging may provide novel diagnostic indicators for the early detection of age-related fibrosis and cardiac dysfunction.
Introduction
The myocardium undergoes a number of structural and functional responses to aging. Across a broad range of species, one consistent hallmark of cardiac aging is a decrease in myocardial reserve capacity (Bokov et al. 2009; Lakatta 1994) . In the absence of pathology or stressors, cardiac performance is often maintained. When superimposed on an increased workload, however, a diminished reserve becomes apparent.
Physiological changes in humans with age include decreased sympathetic signaling (Strait and Lakatta 2012) and decreased heart rate variability (Parati et al. 1997) . Rats and mice also demonstrate reduced heart rate variability with age (Lin et al. 2008; Rossi et al. 2014) . Increases in LV mass, due to increased wall thickness and volumes, and prolonged systolic contraction and diastolic relaxation occur first, before there is an appreciable decline in myocardial performance (Lindsey et al. 2005) . Cardiac aging by itself results in a slight but significant decline in LV function. For example, ejection fraction in mice declines from about 70% in young 7.5-month-old mice to about 60% in 38.1-month-old mice (Lin et al. 2008) .
Aging-associated physiological changes in the human and rat cardiovascular system increase afterload and impair vasodilation, which increases wall stress in the left ventricle (LV) and leads to cardiomyocyte hypertrophy (Strait and Lakatta 2012) . In mice, pressure overload does not naturally occur with aging, as mice are resistant to vascular adaptations, yet cardiomyocyte hypertrophy occurs, indicating that intrinsic myocardial changes are directly responsible for the shift in myocyte phenotype . Increased oxyg e n a n d e n e r g y d e m a n d b y h y p e r t r o p h i c cardiomyocytes creates a low-grade oxygen environment, where free radical production is unbalanced and may damage cellular components (Toprak et al. 2009; Wohlgemuth et al. 2014) .
In response to the hypoxic environment, cardiomyocytes release pro-inflammatory cytokines and chemokines that stimulate an immune response to increase macrophage numbers in the LV (Chiao et al. 2011) . Macrophages are a rich source of matrix metalloproteinases (MMPs), and an unbalanced MMP activity profile has been linked to myocardial aging status in humans with no evidence of cardiovascular disease (Bonnema et al. 2007 ) and across a variety of animal models (Jugdutt et al. 2010; Lindsey et al. 2005) . In aging mice, increased MMP activity has been connected to increased inflammation, extracellular matrix (ECM) deposition, and attenuated angiogenesis capacity .
Indices of aging can include cellular DNA damage and changes in protein structure and organelle function; in particular, mitochondrial dysfunction is well-studied in the context of aging (Sun et al. 2016) . Molecular changes translate to cellular function impairment, including upregulation of apoptosis or necrosis pathways to enhance progressive cardiomyocyte loss (Kajstura et al. 1996) . In the extracellular environment of the aged myocardium, a deregulated ECM leads to fibrosis which results in dysfunction at the cellular, extracellular, and whole organ levels. Aging-related myocardial fibrosis has been observed in mice (Bradshaw et al. 2010; Chiao et al. 2012) , rats (Annoni et al. 1998; Eghbali et al. 1989b) , dogs (Liu et al. 2003) , sheep (Horn et al. 2012) , and humans (Burkauskiene 2005; Gazoti Debessa et al. 2001) .
In this review, we evaluate the aging effects on cardiac ECM and the cell types that regulate or are regulated by ECM. We discuss the relationship between aging and two cardiovascular pathologies (hypertension and myocardial infarction (MI)) and the role of MMPs in these pathologies within the context of aging.
Aging effects on cardiac structure and function
Aging effects on collagen
Myocardial ECM accumulation depends on the balance between synthesis and degradation. Cardiac ECM proteins that accrue with age include glycoproteins, proteoglycans, glycosaminoglycans, matricellular proteins, and integrins (Nguyen et al. 2014) ; effects of aging on these proteins are summarized in Table 1 . A major component of the myocardial ECM is collagen. Total collagen content includes the summation of all collagen types (e.g., I, III, IV, V, VI) and includes all forms of collagen proteins (e.g., full length, fragmented, posttranslationally modified) that reflect ECM quality. Each collagen subtype has a unique tridimensional structure, physicochemical properties, and biological function. Collagens I and III are the most abundant in the myocardium, and collagen I represents 85 ± 5% while collagen III comprises 11 ± 4% of total collagen content in young adult non-human primates (Weber et al. 1988) .
With age, the increase in collagen content in the mouse model is relatively modest (e.g., increases from 1-2 to 2-4% of total LV area) Lin et al. 2008) compared to what is seen after a MI, where the collagen content in the scar region increases to 65% at 4 weeks post-MI (Voorhees et al. 2015) . Collagen represents 6% of total LV protein content in 1-month-old rats and doubles to 12% by 22-26 months of age (Eghbali et al. 1989b) . Therefore, both mice and rats have a doubling in collagen from young to old age, with the difference being the collagen concentration at baseline. While collagen fibril numbers increase, collagen fibril diameter is also larger in old rat hearts (Gazoti Debessa et al. 2001) .
While total amounts vary across species including humans, there is a consistent increase in collagen with age. From autopsies of humans without cardiovascular disease history, myocardial collagen content increased from 3.9 ± 0.8% in 20-25-year-old individuals to 5.9 ± 0.8% in 67-87-year-old individuals (Gazoti Debessa et al. 2001) . Collagen I increased and collagen III decreased in the hearts from autopsies of 80-year-old subjects in comparison to younger subjects (Mendes et al. 2012 ). This shift from collagen III to collagen I would provide a cardiac ECM mechanism that is independent of vascular changes, as the increased ratio of collagens I to III can contribute to LV stiffness (Gazoti Debessa et al. 2001; Mendes et al. 2012) . Collagen I has high tensile strength, while type III collagen is more distensible; therefore, an increased ratio of types I to III can impair cardiac biomechanics (Nguyen et al. 2014) . In contrast to protein levels, transcription of collagens I and III, fibronectin, and β1 integrin messenger RNAs (mRNAs) are decreased in aging LV Horn et al. 2012; Mamuya et al. 1992) . The increased collagen with age, therefore, is due to posttranscriptional regulation rather than increased transcription (Nguyen et al. 2014) .
Collagen cross-linking can increase LV stiffness without altering total collagen content (Horn and Trafford 2016) . Collagen cross-linking, measured by hydroxylysyl pyridinoline concentration, is increased in the LVs of 23-month-old rats (Thomas et al. 1992) . Fibroblasts secrete collagen into the extracellular space in the procollagen form, where it undergoes further processing to become a mature collagen fibril (Prockop and Kivirikko 1995) . Secreted protein acidic and rich in cysteine (SPARC) belongs to the matricellular protein family, and SPARC is involved in (Graf et al. 1997) ↑ increased, ↓ decreased. ECM extracellular matrix, SPARC secreted protein acidic and rich in cysteine cross-linked collagen fibril formation (Bradshaw 2009) . SPARC is predominantly expressed in cardiac fibroblasts, although cardiomyocytes, endothelial cells, and macrophages also exhibit low SPARC expression (Toba et al. 2015) . SPARC increases in the LV of 18-to 29-month-old mice and has been linked to age-related increases in myocardial diastolic stiffness as well as fibrillar and insoluble collagen content. These changes are all blunted by SPARC deletion (Bradshaw et al. 2010) . Aging SPARC-null mice (18-29 months old) also have decreased collagen type III and IV expression and macrophage infiltration compared to aging wildtype control mice (de Castro Bras et al. 2014; Toba et al. 2015) . The decrease in collagen III may result in an increased collagen I to collagen III ratio, which would also explain the increase in myocardial diastolic stiffness. Lysyl oxidase (LOX) activity produces a covalent cross-linking of collagen fibrils, which increases collagen tensile strength and prevent them from degradation by proteases (Biernacka and Frangogiannis 2011) . Increased collagen content and increased LOX cross-linking collagen products have been observed in myocardium of old rats (Thomas et al. 2001 ). Advanced glycation end-products (AGEs) are produced by a non-enzymatic reaction between proteins and sugar residues and can covalently bind other AGEs to form protein-protein cross-links among a variety of ECM components, including collagen, laminin, and elastin (Hartog et al. 2007) . AGEs have been measured in the plasma and associate with the extent of diastolic dysfunction in elderly humans (Campbell et al. 2012) . Age-related diastolic dysfunction can be ameliorated by AGE cross-link breaker treatment in dogs (Asif et al. 2000) . Besides collagen changes, aging-related modifications in fibronectin folding have been reported (Antia et al. 2008) . Increased stretching of fibronectin fibrils can lead to partial unfolding of the secondary structure. This change in protein structure may shift cell and enzyme recognition sites on ECM proteins by physically modifying binding site availability (Antia et al. 2008 ).
Aging effects on MMPs
MMPs are defined by their ability to proteolytically process ECM components and as such are key regulators of ECM turnover. MMPs are secreted in their preactivated zymogen form, in which an inhibitory propeptide domain is bonded by a cysteine residue to the Zn 2+ ion present on the catalytic domain. Classical MMP activation removes the inhibitory pro-peptide domain to disrupt the cysteine switch. MMP activity, however, does not solely rely on activation, as MMPs can have activity in the presence of substrate that is not dependent on pro-domain cleavage (Kandasamy et al. 2010) . MMPs are endogenously inhibited in the tissue by interaction with the tissue inhibitors of metalloproteinases (TIMPs), of which four have been identified. Aging effects on MMPs levels are summarized in Table 2 . MMP-2, MMP-7, TIMP-1, TIMP-2, and TIMP-4 increase in the plasma of elderly human subjects, and MMP-7, TIMP-1 and -4 correlate with diastolic dysfunction variables (Bonnema et al. 2007 ). In mice, plasma MMP-9 concentration positively correlates with age and with monocyte chemotactic protein-1 (Yabluchanskiy et al. 2015) . MMP-1, MMP-2, MMP-3, and MMP-14 increase in the LV of 31-month-old rats that underwent exercise training vs. an age-matched sedentary group (Kwak et al. 2011) . MMP-3, MMP-12, MMP-13, and MMP-14 decrease in the soluble fraction of 23-month-old CB6F1 LV compared to young controls, while MMP-3, MMP-8, and MMP-14 increase in the insoluble ECM-bound fraction (Lindsey et al. 2005) . MMP-28 is the newest member of the MMP family, and MMP-28 increases in the LV of 20-month-old mice .
MMP functions go beyond cleaving ECM substrates. For example, MMP-9 can process a number of cytokines, growth factors, and other MMPs, including interleukin (IL)-1β, IL-6, and IL-8, tumor necrosis factor α (TNF-α), endothelin-1, transforming growth factor beta (TGF-β), vascular endothelial growth factor (VEGF), osteopontin, and MMP-2, MMP-9, and MMP-13 (Cauwe et al. 2007; Egeblad and Werb 2002; Lindsey et al. 2016; Sternlicht and Werb 2001) . A number of intracellular substrates have been identified (Cauwe and Opdenakker 2010) . Figure 1 illustrates how aging can induce MMPs to modulate a number of biological functions.
Of the MMPs evaluated to date, a number of studies have assessed MMP-9 in cardiac aging. There is strong evidence that MMP-9 is a major mediator for increased stiffness in the aging LV . MMP-9 is predominantly expressed in leukocytes, with low expression in cardiomyocytes (Huet et al. 2015) . Macrophage-derived MMP-9 has been implicated in cardiac aging (Chiao et al. 2011) . MMP-9 expression increases twofold in the LV of aged mice. Plasma MMP-9 positively correlates with LV enddiastolic dimension (Chiao et al. 2011) . Moreover, aging MMP-9-null mice have reduced expression of cadherin 1, integrin α V , and TIMP-3 ). Together, MMP-9 deletion-associated changes result in increased angiogenesis and decreased cardiomyocyte hypertrophy during aging . In contrast, MMP-28 deletion amplifies inflammation and of note, MMP-9 is elevated in the absence of MMP-28, suggesting cross-talk among MMPs (Ma et al. 2015; Ma et al. 2012; Iyer et al. 2016 ).
Aging effects on cardiac fibroblast cell physiology Cardiac fibroblasts are the major producer of ECM, including collagen. In this review, we classify all (Xu and Finkel 2002) . Low nutrient levels can feedback to increase sirtuin-1 and sirtuin-3 activities, which are associated with increased mitochondrial biogenesis, mitochondrial protein synthesis, antioxidant defense, and life span (Sack and Finkel 2012) . Little is currently known about the effect of fibroblast cell metabolism on cell physiology, particularly in the context of aging.
Aging effects on cardiomyocyte cell physiology
In the aging LV, there are quantitative and qualitative changes in the cardiomyocyte population, with hypertrophy characterizing the early phase of response. Myocyte cell volumes, cross-sectional areas, and cell length all increase with aging, resulting in reduced intercardiomyocyte space (Anversa et al. 2005; Yabluchanskiy et al. 2014) . Together with cardiomyocyte hypertrophy, the number of multi-nucleated cardiomyocytes increases (Anversa et al. 1990; Olivetti et al. 1987 ). Age-induced cardiomyocyte hypertrophy can be accompanied by a deficiency in oxygen supply (Khan et al. 2002) . While some reports indicate that hypertrophy is less efficient and uses more oxygen, other reports indicate that hypertrophy is more efficient and uses less oxygen (Gunning and Coleman 1973) . The setting of hypertrophy (physiological vs. pathological) may explain the differences observed, and further studies are warranted. Hypoxia, in part through upregulation of hypoxia inducible factor 1, is a powerful stimulus for the expression of angiogenic signaling factors. Reactive oxygen species (ROS) production resulting from impaired mitochondrial function stimulates hypoxia inducible factor 1 activation (Liu and Finkel 2014) . Cardiomyocytes contribute to ECM remodeling by expressing collagen type IV (Eghbali et al. 1989a ), MMP-2, MMP-9, MMP-14, and all TIMP subtypes (Bildyug et al. 2015; Riches et al. 2009; Vanhoutte and Heymans 2010) .
Cardiomyocyte aging is accompanied by organelle changes. Myocyte aging is associated with the accumulation of mitochondrial DNA mutations, protein oxidation, and altered biogenesis, which leads to impaired bioenergetic efficiency and increased ROS levels, which enhance myocyte apoptosis rates and induce an inflammatory reaction (Martin-Fernandez and Gredilla 2016) . Mitochondrial function and life span are improved by the genetic inhibition of the mammalian target of rapamycin (mTOR), a serine-threonine kinase that functions as an intracellular energy sensor (Finkel 2015; Wu et al. 2013) .
Sarcoplasmic reticulum function and calcium signaling are impaired with age. The sarcoplasmic reticulum Ca 2+ pump (SERCA2) regulates cardiomyocyte contraction and relaxation by handling intracellular Ca 2+ stores; SERCA2 activity is decreased in aging hearts (Kaplan et al. 2007 ). The overall result of cardiomyocyte aging is a decrease in cardiomyocyte numbers, which have been observed in both animal experiments and human clinical studies (Anversa et al. 1986; Olivetti et al. 1991) . Regression analysis suggests that cardiac aging process is characterized by a loss of 38 million cardiomyocyte nuclei per year in human LVs (Olivetti et al. 1991) .
The endocrine system has an impact on cardiomyocytes during aging, especially the renin angiotensin system (RAS). Angiotensin II (Ang II) and angiotensin converting enzyme (ACE) are increased in cardiac tissue with age Lakatta and Levy 2003) . Ang II can directly induce cardiomyocyte hypertrophy, fibrosis, apoptosis, LV stiffness, and diastolic dysfunction (Domenighetti et al. 2005) . Furthermore, treatment with the ACE inhibitor enalapril and the angiotensin II type 1 receptor antagonist losartan ameliorates age-related cardiac changes (Basso et al. 2007 ). ACE inhibitors have been shown to inhibit MMP-9 activity by interacting with the proteolytic site (Yamamoto et al. 2007a; Yamamoto et al. 2007b) , which can partially explain the beneficial effects of ACE inhibitors on cardiac aging.
Aging effects on cardiac macrophage physiology An enhanced chronic inflammatory status is a hallmark of cardiac aging (Franceschi 2007) . Mitochondrial DNA (mtDNA) from dead cells may play a role in cardiac inflammation by stimulating endogenous cardiac cell inflammatory gene expression and by serving as a direct or indirect chemoattractant for inflammatory cells. Unlike nuclear DNA, mtDNA is not methylated and triggers macrophage activation by engaging with toll-like receptors (Sun et al. 2016) . Monocyte chemoattractant protein-1 (MCP-1 or CCL2) is a chemokine with an agedependent increase in circulating levels and LV expression (Chiao et al. 2011; Deshmane et al. 2009 ). Macrophage content in the LV and MMP-9 expression in the LV and plasma are also elevated in aging mice (Chiao et al. 2011 ). Plasma MCP-1 and MMP-9 positively correlate with end-diastolic dimension, indicating MCP-1 and MMP-9 are circulating biomarkers of cardiac aging (Chiao et al. 2011) .
Beyond macrophage quantity, LV macrophage polarization (M1 vs. M2 phenotype) is also altered by aging (Ma et al. 2015) . MMP-9 deletion suppresses these phenotypic changes by increasing macrophage mRNA levels of CD206 and Fizz1 and by preventing the agerelated shift from F4/80 + CD206 + M2 cells to F4/ 80 + CD206 − M1 cells (Ma et al. 2015) . Macrophage accumulation is also decreased in the LVs of old SPARC-null mice (Toba et al. 2015) . Isolated peritoneal macrophage stimulated with SPARC recombinant protein showed increased expression of M1 proinflammatory polarization markers (Ccl3, Ccl5, TNF-α, and IL-12) and decreased expression of antiinflammatory M2 polarization markers (Arg1 and Mrc1) (Toba et al. 2015) . Therefore, in addition to mediating ECM events in cardiac aging, MMP-9 and SPARC regulate cell physiology and signaling.
Aging effects on myocardial endothelial cell physiology Endothelial dysfunction is highly associated with age. Impaired nitric oxide (NO) bioavailability is a major cause of diminished vasodilation, and endothelial NO synthase (eNOS) expression is decreased with age (Brandes et al. 2005) . Moreover, reactive oxygen species (ROS), including superoxide radical (O 2 − ), are increased with age (Herrera et al. 2010) . ROS can rapidly scavenge NO, decreasing its bioavailability and producing other free radicals such as reactive nitrogen species (RNS). In addition, ROS can uncouple eNOS by depleting tetrahydrobiopterin (BH4) stores. This uncoupled eNOS converts L-arginine to O 2 − instead of NO, creating a positive feedback loop to free-radical production (Zweier et al. 2011) . ROS and RNS can promote protein structural modifications by reacting with amino acid residues. Protein oxidation or nitrosylations can enhance or diminish activity. For example, free radicals can disrupt the cysteine switch between the inhibitory and catalytic domains of MMPs, resulting in an active fulllength enzyme (Chow et al. 2007 ). Unbalanced ROS production can activate nuclear factor-kappa B (NFκB), leading to a pro-inflammatory shift in the endothelial gene expression profile (Donato et al. 2007 ). Increased ROS contributes to activation of the TNF-α signaling pathway and impaired mitochondrial activity (Herrera et al. 2010) . Thus, oxidative stress can accelerate endothelial cell senescence by decreasing proliferative responses to mitotic stimuli (Toussaint et al. 2002) . One index of endothelial dysfunction is vascular permeability. Increased vascular permeability and cadherin-1 expression were observed in the LVs of 15-18-month-old mice compared to 6-8-month-old mice . Cadherin-1 is a transmembrane protein that forms adherens junctions between endothelial cells, and an increase in cadherin-1 may indicate an attempt to preserve vascular permeability in the aged LV. Moreover, integrin αV decreases with age and in line with the observed vessel rarefaction. MMP-9 gene deletion blunts vascular permeability in 15-18-month-old mice, indicating a role for MMP-9 in maintaining vessel integrity .
Vascular endothelial growth factor (VEGF) is an essential factor that regulates angiogenesis by inducing endothelial cell growth, migration, and tube formation . While VEGF mRNA increases in the LVs of both 15-18-month-old wild-type and MMP-9-null mice, vessel numbers assessed by griffonia simplicifolia lectin I staining only increase in the null group . These results indicate an age-related disconnect between angiogenic mediators released by myocardial cells and their effectiveness . Human dermal microvascular endothelial cells derived from elderly and neonatal individuals showed decreased VEGF mRNA and protein in the elderly group, indicating likely organ specific differences (Ahluwalia et al. 2014) .
Coronary blood flow is decreased in the hearts of 30-month-old rats compared to 6-month-old young rats, and capillary density was decreased in the mid and apex regions (Khan et al. 2001) . Decreased blood perfusion, decreased new vessel formation, and impaired vasodilation are associated with age to generate an environment that can maintain basal function but has reduced reserve potential.
Aging effects on associated cardiovascular pathologies
Aging and hypertension Cardiovascular aging affects the walls of large arteries in humans, particularly the aorta. Over time, the aorta becomes thicker and loses its elastic nature. This process results in arterial stiffness and increases in pulse wave velocity. Of note, the age-related increase in blood pressure does not occur in mice (Lin et al. 2008) . Thus, the mouse is a particularly interesting species to study aging effects on the heart without confounding age-related blood pressure effects. Intrinsic cardiac aging in the murine model closely recapitulates age-related changes in humans who do not have accompanying hypertension, including LV hypertrophy, fibrosis, and diastolic dysfunction (Dai and Rabinovitch 2009) .
Aging-induced hypertension has been related to adverse remodeling with accompanying endothelial dysfunction, LV hypertrophy, and diastolic dysfunction (Wang and Shah 2015) . In aging Wistar rats, mRNA transcription is decreased for type III collagen, fibronectin, and β1 integrin in comparison to young Wistar rats. In contrast, increased transcription and expression of type III collagen, fibronectin, and β1 integrin are observed in aging spontaneously hypertensive rats (SHR) compared to young SHR (Mamuya et al. 1992) . These data suggest that in the rat, aging may not increase transcription of ECM components when blood pressure is normal. In this case, post-transcriptional modifications may be contributing to the increased ECM deposition in aging hearts.
Aging and MI
Aging worsens post-MI LV remodeling outcomes. There is reduced collagen scar deposition in healing infarcts of old mice (>24 month old) compared to young mice (2-3 month old); collagen deposition in resolving infarctions is similar, indicating delayed kinetics (Yang et al. 2008) . Mice >2 years old have decreased expression of osteopontin mRNA compared to young mice 2-3 months old. TGF-β1, TGF-β2, and TGF-β3 levels are not significantly different in the infarcted/reperfused regions of both old and young mice (Bujak et al. 2008) . The upregulation of TGF-β stimulates the synthesis of fibrous connective tissue, which reduces the flexibility of the myocardium and increases myocardial stiffness. In addition, an imbalance between MMPs and TIMPs leads to ECM changes that stimulate cardiac dilatation due to excessive ECM degradation. These changes can lead to diastolic dysfunction and eventually heart failure. Aging, therefore, changes the ECM environment, such that the response to MI injury is less effective (Nguyen et al. 2014) . The positive correlation between age and LV dilation in post-MI wild-type mice is not observed with MMP-9 deletion (Yabluchanskiy et al. 2015) . In addition, MMP-9 deletion improves post-MI survival rates. Moreover, MMP-9 deletion does not change the number of macrophages in the LV, but does increase the expression of M2 polarization markers, suggesting an improved post-MI repair profile. Fig. 2 Aging-related events involved in the development of cardiac dysfunction. Aging leads to increased afterload and decreased vasodilation, and these are the inputs for cardiomyocyte hypertrophy. Increased oxygen and energy demand results in hypoxia, which favors an increase of reactive oxygen species (ROS) levels and release of pro-inflammatory factors. As a result, there is an increase in immune cell infiltration, such as macrophages. Macrophages secrete matrix metalloproteinases (MMPs), which leads to increased extracellular matrix (ECM) deposition, decreased angiogenesis, and cardiac dysfunction
Future directions and conclusion
The myocardium undergoes a number of cellular and extracellular responses during aging, leading to increased LV stress and diastolic dysfunction (Fig. 2) . While much knowledge has been obtained, there are several avenues fruitful for future examinations. One direction is to better understand how MMP activities could be modified to prevent or slow the development of excessive cardiomyocyte hypertrophy and ECM deposition. Aging is a resetting of baseline values to set a new homeostasis, and attempts to delay or prevent this shift may improve the cardiac aging phenotype.
Proteomics is a powerful tool with multiple applications for cardiac aging studies. Proteomics is used to catalogue MMP substrates to further elucidate cell signaling pathways modified by MMPs (Cauwe et al. 2009; Eckhard et al. 2016; Ma et al. 2012; Iyer et al. 2016) . Unbiased proteomics explorations will continue to elucidate molecular pathways involved in cardiac aging and identify useful biomarkers of cardiac aging. Genomics screens also provide a method of identifying gene pathways important for aging (Johnson et al. 2011; Yamamoto and Takai 2009 ). As we amass big data on cardiac aging, computational models at the molecular, cellular, and organ levels will be useful. For example, a computational model of fibroblast changes during the time course of aging will be useful for understanding intracellular fibroblast communication, as well as intercellular communication that includes fibroblast connections to macrophages, cardiomyocyte, and endothelial cells (Saucerman 2016) . Understanding the relationship between myocyte hypertrophy, inflammation, and fibrosis will also be an important future avenue of research (Nahrendorf 2016; Turner 2016) .
While this review focused on aging-related changes in ECM and MMPs and their relationship with hypertension and MI, a similar template can be applied for other relevant molecular components and as a broad application to other cardiovascular diseases that involve MMPs and have aging as a risk factor, such as diabetes, hyperlipoproteinemia, renal failure, and also cardiovascular events as stroke and aneurysms. In conclusion, understanding the dynamic ECM changes that occur over the time continuum of cardiac aging will provide us novel insight into the aging process that has implications for both physiology and pathophysiology.
